What is Endospan?
Endospan is dedicated to developing innovative endovascular treatment solutions, with a primary focus on its NEXUS Aortic Arch Stent Graft System. This system is engineered to tackle the complex anatomical challenges presented by aortic arch aneurysms. While the company offers custom-made devices, their availability is contingent on local regulatory approvals and they are not presently accessible in the U.S. market. Endospan's mission is to address critical unmet needs in aortic arch repair, thereby aiming to reduce the incidence of stroke complications associated with these vascular conditions.
How much funding has Endospan raised?
Endospan has raised a total of $35M across 2 funding rounds:
Private Equity
$10M
Other Financing Round
$25M
Private Equity (2015): $10M with participation from Haisco Pharmaceutical Group Co.
Other Financing Round (2024): $25M led by Artivion
Key Investors in Endospan
Artivion
Artivion is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair.
Haisco Pharmaceutical Group Co.
Haisco Pharmaceutical Group is a China-based public pharmaceutical company dedicated to providing the best medical products in specialized areas to patients and the company's community. With extensive experience, Haisco is capable of developing, manufacturing and commercializing innovative drug products as well as generic drug products with high technical barrier in the company's focused areas.
What's next for Endospan?
The recent major enterprise-level funding and strategic investment indicate Endospan is poised for significant expansion and product development. This capital infusion is likely to accelerate the company's efforts to gain regulatory clearance in key markets, including the United States, and to scale its manufacturing and distribution capabilities. The backing from established entities suggests confidence in Endospan's technology and its potential to capture a substantial share of the vascular repair market. Future developments will likely focus on clinical validation, market penetration, and potentially further strategic partnerships to enhance its global reach.
See full Endospan company page
